PROF Company Profile and Key Details

Profound Medical Corp. has 36.34 million shares outstanding. The public float is 34.73 million shares, elevated short interest at 5.77% of float. This equals 1.85 million shares. The short ratio is 23.28 days. Institutional investors hold 46.42% of the float. Insiders own 4.07%. Schweitzer John H. holds 72.50 million shares, Menawat Arun Swarup has 587.09 thousand shares and HOFER MICHAEL has 500.00 thousand shares.

Short-term trend indicators are mixed aligned (SMA20 12.13%, SMA50 4.11%, SMA200 28.3%). The stock’s 14-day RSI is 61.71 (firm momentum), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.13% below its high and over 106.78% above its low. Average 10-day trading volume of 161.86 thousand shares is significantly above the 3-month average of 82.26 thousand, indicating heightened recent market interest.

Profound Medical Corp. generated EPS of -$1.34 over the past year. Five-year average earnings growth is 3.91%. Wall Street analysts project EPS growth of 15.12% annually over the next five years. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.27. Next year's EPS is expected at $3.74. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $12.00. The high target offers 62.6% upside. The low target suggests 62.6% downside. The mean target is $12.00. This offers 62.6% upside. Profound Medical Corp. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -20.83%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -35.48% in March 06, 2025.

Profound Medical Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.76. This means the shares are trading below this model’s fair value.

Profound Medical Corp. (NASDAQ:PROF) closed at $7.38 USD, gaining $0.13 (1.79%) from the previous close of $7.25. The stock is currently mid-range between its 52-week high and low $3.76 and $8.95. With a market capitalization of about $268.17 million, Profound Medical Corp. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.53). Key stats such as the average daily volume over the past year has been around 82.22 thousand shares, volume is running light vs its 52-week average. Headquartered in Mississauga, ON, Profound Medical Corp. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Arun Swarup Menawat, the company employs approximately 162 people and listed since October 29, 2019. Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions.

Profound Medical Corp. (NASDAQ:PROF) shares are flat 0.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Profound Medical Corp. trading at a premium to the broader market with a P/E of -5.95. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.00, suggesting 76.15% upside. Our AI forecast model points to short-term strength (1.76% over two weeks), a medium-term fall (-12.87% over three months), and a longer-term gain (230.49% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Profound Medical Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.76%, with price expected at $7.51 by August 14, 2026, within a range of $7.21 to $7.83 3-Month Outlook: Projected fall of -12.87%, reaching $6.43 by October 28, 2026, with a range of $6.06 to $6.80. 1-Year Outlook: Projected gain of 230.49%, with price at $24.39 by July 30, 2027, within a range of $21.62 to $29.84.

Profound Medical Corp. trades at a P/E ratio of -5.95, slightly below the S&P 500 average, with a price-to-sales ratio of 14.42 and a price-to-book ratio of 4.53 trading at moderately above to book value. The P/FCF stands at -6.97, also below market averages.